No clinical studies found
No published clinical study of 5-Amino-1MQ was identified on PubMed. The available record is preclinical research and user reported experience. Reported in the cited paper.
SourceResearch Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase, not a peptide. It is studied for fat metabolism and metabolic regulation, with the published record limited to preclinical work and no human clinical trials.
Supplier listings
Form
Show prices as
Size
83 listings · 5-Amino-1MQ
In stock50mgseen 2w ago
In stock50 mg · 10 vialsseen 5w ago
In stock5mgseen 7w ago
In stock10mgseen 7w ago
In stock5mgseen 7w ago
In stock5mgseen 7w ago
In stock5mgseen 5w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock5mgseen 7w ago
In stock50mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 5w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock5mgseen 2w ago
In stock10mgseen 7w ago
In stock10mgseen 4w ago
In stock5mgseen 7w ago
In stock50mgseen 2w ago
In stock5mgseen 7w ago
In stock10mgseen 7w ago
In stock50mgseen 2w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 6w ago
In stock50mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock50mgseen 2w ago
In stock50mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 6w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock50mgseen 7w ago
In stock50mgseen 7w ago
In stock5 mg · 2 vialsseen 3w ago
In stock50mgseen 7w ago
In stock10mgseen 7w ago
In stock50mgseen 7w ago
In stock50mgseen 7w ago
In stock50mgseen 7w ago
In stock50mgseen 7w ago
In stock10mgseen 7w ago
In stock50 mg · 10 vialsseen 7w ago
Out of stock50mgseen 7w ago
Overview
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase, not a peptide. It is studied for fat metabolism and metabolic regulation, with the published record limited to preclinical work and no human clinical trials.
What the research reports
Outcomes described across the published 5-Amino-1MQ literature and ongoing study. Read each as research context, not a promised result.
NNMT enzyme inhibition work
Blocks nicotinamide N-methyltransferase, an enzyme involved in energy metabolism and the regulation of adipose tissue. Described in the research record.
Fat mass preclinical research
Mouse work in diet induced obesity reported reduced fat mass, the finding behind most of the interest in this compound. Reported in research settings.
Oral administration only use
The published preclinical evidence for fat-mass reduction used injected dosing in mice, not oral. Research-grade 5-Amino-1MQ is commonly sold and used orally, but oral administration has not been directly tested in the published studies behind this compound's efficacy claims.
Nicotinamide pathway effects
Inhibition shifts nicotinamide handling, which is why protocols often suggest spacing it apart from NAD+ precursors. Described in the research record.
Metabolic target research
NNMT is an emerging target in metabolic research, so the compound is studied as a probe as much as a therapy. Noted across the published research record.
Clinical evidence
The published record for 5-Amino-1MQ, labeled by strength so you can see what is settled and what is emerging.
No published clinical study of 5-Amino-1MQ was identified on PubMed. The available record is preclinical research and user reported experience. Reported in the cited paper.
SourcePublished mouse research from 2018 reported reduced fat mass in diet-induced obese animals after NNMT inhibition by this compound, using injected rather than oral dosing. Reported in the cited paper.
SourceBroader NNMT literature covers the enzyme's role in metabolism and its overexpression across several tumour types, relevant context for safety. Reported in the cited paper.
SourceInteractions
Questions